July 2019 Issue Table Of Contents

From The Editor

• Let’s Talk Two Taboo Topics — Money And Politics

Feature Articles

• Bassil Dahiyat’s Two-Decade Biotech Startup Odyssey
• Increasing Diversity Among Leadership And Boards
• Ending Generic Drug Shortages At Hospitals: A Capitalist Goes Nonprofit

Capitol Perspectives

• Restructuring Of Medicare Part D Imminent

CEO Corner

• Do You Know The 4 Pillars To Drive Stakeholder Value?

From Principles and Policy to Execution

• Patient Satisfaction With Health Systems Is About Value, Not Just Cost

Companies To Watch

• Angion

Industry Research

• The Geographic Distribution Of 2019’s CRO Market Size

Inside The Industry

• How To Make Sure Restrictive Covenants Survive A Restructuring
• Success In HIV Treatments Creates Additional Challenges For Drug Developers
• The Many Shades Of VC/Repeat Entrepreneur Relationships
• Using War Games To Predict Competitors’ Moves
• Tackling Cell & Gene Therapy Financing & Manufacturing Challenges

Leadership Lessons

• Innovation Capital: How Do Leaders Win Support for their Ideas?

Ask The Board

• What Is Your Opinion On The Present Reimbursement Landscape In U.S. Healthcare?
• How Can We Ensure We Don’t Overburden Patients With Requests For Input Into Our Trial Designs And Disease Burden Questions?
• It Seems The High Cost Of Drug Development Is Unsustainable. Should New Regulatory Pathways Be Considered?